What is AOA Dx?
AOA Dx is a Boston-based biotechnology company dedicated to bringing the first accurate, non-invasive early-stage ovarian cancer diagnostic test to market. Their mission is to significantly improve clinical practice, reduce patient mortality rates, and deliver cost savings to healthcare payers. By focusing on early detection, AOA Dx aims to address a critical unmet need in women's health, potentially transforming patient outcomes and the economic landscape of cancer care.
How much funding has AOA Dx raised?
AOA Dx has raised a total of $24M across 2 funding rounds:
Angel/Seed
$7M
Other Financing Round
$17M
Angel/Seed (2022): $7M with participation from AlleyCorp companies, Joyance Partners, Kyto Technology & Life Science, Pioneer Fund, Launchpad Venture Group, The Helm Management, Avestria Ventures Management, RH Capital, Beacon Angels, SideCar Angels, and TBD Angels
Other Financing Round (2023): $17M led by RH Capital, Y Combinator, and Good Growth Capital
Key Investors in AOA Dx
Kyto Technology & Life Science
Kyto Technology & Life Science is a venture capital firm that focuses on investing in early-stage startups, particularly in the life sciences sector. They aim to provide a diversified and vetted investment vehicle for top-tier angel-stage companies.
Avestria Ventures Management
Avestria Ventures Management is a venture capital firm specializing in early-stage women's health and life science companies, with a particular emphasis on supporting female founders and addressing underfunding in this critical area.
Y Combinator
Y Combinator is a renowned startup accelerator that provides seed funding and mentorship to early-stage companies, helping them to scale and achieve significant growth.
What's next for AOA Dx?
With the recent influx of major strategic investment, AOA Dx is poised to accelerate its development and commercialization efforts. This capital infusion is expected to fuel the final stages of product development, regulatory approvals, and market entry. The company's focus on a non-invasive diagnostic test positions it to capture a significant share of the growing oncology diagnostics market, with potential for substantial growth and impact on patient care.
See full AOA Dx company page
